Meta-analysis of all immune epitope data in the flavivirus genus: Inventory of current immune epitope data status in the context of virus immunity and immunopathology

Viral Immunology

Volumn 23, Issue 3, 2010, Pages 259-284

  Vaughan, Kerrie ^a   Greenbaum, Jason ^a   Blythe, Martin ^a   Peters, Bjoern ^a   Sette, Alessandro ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; DENGUE VACCINE; EPITOPE; FLAVIVIRUS VACCINE; GENOMIC RNA; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; T LYMPHOCYTE ANTIGEN; TICK BORNE ENCEPHALITIS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; WEST NILE VACCINE; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CLINICAL RESEARCH; CLINICAL TRIAL; CROSS REACTION; DATA BASE; DENGUE; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; FEVER; FLAVIVIRUS; FLAVIVIRUS INFECTION; GENOMICS; GEOGRAPHY; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; KUNJIN VIRUS; LOUPING ILL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; META ANALYSIS; MORTALITY; MURRAY VALLEY ENCEPHALITIS; MURRAY VALLEY ENCEPHALITIS VIRUS; NONHUMAN; PHENOTYPE; REVIEW; SERODIAGNOSIS; SEROLOGY; ST LOUIS FLAVIVIRUS; ST. LOUIS ENCEPHALITIS; SYSTEMATIC REVIEW; T LYMPHOCYTE; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS IMMUNITY; VIRUS STRAIN; VIRUS TRANSMISSION; WEST NILE FEVER; WEST NILE FLAVIVIRUS; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; ANIMAL; ANIMAL DISEASE; ARTICLE; IMMUNOLOGY; PATHOLOGY;

ANIMALIA; DENGUE VIRUS; FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; WEST NILE VIRUS;

ANIMALS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; VIRAL VACCINES;

EID: 77954158557     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2010.0006     Document Type: Review

References (113)

1. Allwinn R, Doerr HW, Emmerich P, Schmitz H, and Preiser W: Cross-reactivity in flavivirus serology: new implications of an old finding? Med Microbiol Immunol 2002;190: 199-202.
2. Appanna R, Huat TL, See L, Tan PL, Vadivelu J, and Devi S: Cross-reactive T-cell responses to the nonstructural regions of dengue viruses among dengue fever and dengue hemorrhagic fever patients in Malaysia. Clin Vaccine Immunol 2007;14:969-977.
3. Barrett PN, and Dorner F: Tick-borne encephalitis vaccine. In: Vaccines, 2nd ed. (Plotkin SA, and Mortimer EA, eds.). WB Saunders Company, Philadelphia, 1994, pp. 715-727.
4. Barrett AD, and Gould EA: Antibody-mediated early death in vivo after infection with yellow fever virus. J Gen Virol 1986;67:2539-2542.
5. Bashyam HS, Green S, and Rothman AL: Dengue virusreactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous virus serotypes. J Immunol 2006;176:2817-2824.
6. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, and Rager-Zisman B: Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 2003;188:5-12. (Pubitemid 36829736)
7. Blaney JE, Johnson DH, Manipon GG, Firestone CY, Hanson CT, Murphy BR, and Whitehead SS: Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 2002;300:125-139.
8. Blythe M, Zhang Q, Vaughan K, et al.: An analysis of the epitope knowledge related to Mycobacteria. Immunome Res 2007;3:10.
9. Brandriss MW, Schlesinger JJ, Walsh EE, and Briselli M: Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 1986;67(Pt 2):229-234.
10. Brinton MA, Kurane I, Methew A, Zeng L, Shi PY, Rothamn A, and Ennis FA: Immune mediated and inherited defences against flaviviruses. Clin Diagn Virol 1998;10:129-139.
11. Bui HH, Peters B, Assarsson E, Mbawuike I, and Sette A: Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci USA 2007;104:246-251.
12. Centers for Disease Control and Prevention: Questions and Answers About Japanese Encephalitis. www.cdc.gov/ ncidod/dvbid/jencephalitis/qa.htm
13. Centers for Disease Control and Prevention: West Nile activity-United States, 2006. MMWR Morb Mortal Wkly Rep 2007;56:556-559.
14. Centers for Disease Control and Prevention 3: SLEV: www.cdc.gov/ncidod/ dvbid/sle/Sle-FactSheet.html.
15. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, and Brandt WE: Antigenic relationships between flaviviruses as determined by crossneutralization tests with polyclonal antisera. J Gen Virol 1989;70(Pt 1):37-43.
16. Camenga DL, Nathanson N, and Cole GA: Cyclophosphamide- potentiated West Nile viral encephalitis: Relative influence of cellular and humoral factors. J Infect Dis 1974;130:634-641.
17. Charlier N, Leyssen P, De Clerq E, and Neyts J: Rodent models for the study therapy against flavivirus infections. Antiviral Res 2004;63:67-77.
18. Chen HC, Lai SY, Sung JM, et al.: Lymphocyte activation and hepatic cellular infiltration in immunocompetent mice infected by dengue virus. J Med Virol 2004;73:419-431.
19. Chung KM, Nybakken GE, Thompson BS, Engle MJ, Marri A, Fremont DH, and Diamond MS: Antibodies against West Nile virus nonstructural (NS)-1 protein prevent lethal infection through Fc gamma receptor-dependent and independent mechanisms. J Virol 2006;80:1340-1351.
20. Churdboonchart V, Bhamarapravati N, Peampramprecha S, and Sirinavin S: Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg 1991;44:481-493.
21. Co MDT, Terajima M, Cruz J, Ennis FA, and Rothman AL: Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35- restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 2002;293:151-163.
22. Cologna R, Armstrong PM, and Rico-Hesse R: Selection for virulent dengue viruses occurs in humans and mosquitoes. J Virol 2005;79:853-859.
23. Crill WD, Trainor NB, and Chang GJJ: A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles, J Gen Virol 2007;88:1169-1174.
24. Dewasthaly SS, Bhonde GS, Shankarraman V, Biswas SM, Ayachit VM, and Gore MM: Chimeric T helper-B cell peptides induce protective response against Japanese encephalitis virus in mice. Protein Pept Lett 2007;14:543-551.
25. Diamond MS, Shrestha B, Marri A, Mahan D, and Engle M: B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003;77:2578-2586.
26. Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, and Engle M: A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med 2003;198:1853-1862.
27. Ellis BR, and Barrett AD: The enigma of yellow fever in East Africa. Rev Med Virol 2008;18:331-346.
28. Engle MJ, and Diamond MS: Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 2003;77:12941-12949.
29. Falconar AKI: Antibody responses are generated to immunodominant ELK/KLE-type motifs on the nonstructural- 1 glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis, pathogenesis, and vaccine design. Clin Vaccine Immunol 2007;14: 493-504.
30. Gagnon SJ, Zeng W, Kurane I, and Ennis FA: Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotypecross- reactive human CD4+ cytotoxic T-lymphocyte clones. J Virol 1996;70:141-147.
31. Garcia G, Vaughn DW, and Del Angel RM: Recognition of synthetic oligopeptides from nonstructural proteins NS1 and NS3 of dengue-4 virus by sera from dengue virusinfected children. Am J Trop Med Hyg 1997;56:466-470.
32. Gould EA, and Buckley A: Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J Gen Virol 1989;70:1605-1608.
33. Gould EA, Buckley A, Groeger BK, Cane PA, and Doenhoff M: Immune enhancement of yellow fever virus neurovirulence for mice: studies of mechanisms involved. J Gen Virol 1987;68:3105-3112.
34. Gould EA, and Solomon T: Pathogenic flaviviruses. Lancet 2008;371:500-509.
35. Halstead SB: Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003;60: 421-467.
36. Halstead SB, Shotwell H, and Casals J: Studies on the pathogenesis of dengue infection in monkeys: Clinical laboratory response to heterologous infection. J Infect Dis 1973;128:15-22.
37. Hamdan A, Green P, Mendelson E, Kramer MR, Pitlik S, and Weinberger M: Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 2002;4: 160-162.
38. Holzmann H, Utter G, Norrby E, Mandl CW, Kunz C, and Heinz FX: Assessment of the antigenic structure of tickborne encephalitis virus by the use of synthetic peptides. J Gen Virol 1993;74:203-2035.
39. Huang KJ, Yang YC, Lin YS, et al.: The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 2006;176:2825-2832.
40. Imrie A, Meeks J, Gurary A, Sukhbataar M, Kitsutani P, Effler P, and Zhao Z: Differential functional avidity of dengue virus-specific T cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol 2007;81:10081-10091.
41. Jacobs SC, Stephenson JR, and Wilkinson GWG: Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1. J Genl Virol 1994;75:2399-2402.
42. Kaiser R, and Holzmann H: Laboratory findings in tickborne encephalitis. Correlation with clinical outcome. Infection 2000;28:78-84. (Pubitemid 30189612)
43. Karabatsos N: International Catalogue of Arboviruses, 3rd ed. American Society of Tropical Medicine and Hygiene, San Antonio, Texas, 1985.
44. Kesson AM, Blanden RV, and Mullbacher A: The primary in vivo murine cytotoxic T cell response to the flavivirus, West Nile. J Gen Virol 1987;68:2001-2006.
45. Kimura-Kuroda J, and Yasui K: Topographical analysis of antigenic determinants on envelope glycoprotein V3 (E) of Japanese encephalitis virus, using monoclonal antibodies. J Virol 1983;45:124-132.
46. King NJ, Getts DR, Getts MT, Rana S, Shrestha B, and Kesson AM: Immunopathology of flavivirus infections. Immunol Cell Biol 2007;85:33-34.
47. Kreil TR, and Eibl MM: Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol 1997;71: 2921-2927.
48. Kurane I, Brinton MA, Samson AL, and Ennis FA: Dengue virus-specific human CD4+, CD8-cytotoxic T cell clones: multiple patterns of virus cross-reactivity recognized by the NS3-specific T cell clones. J Virol 1991;65:1823-1828.
49. Kutubuddin M, Kolaskar AS, Galande S, Gore MM, Ghosh SN, and Banerjee K: Recognition of helper T cell epitopes in envelope (E) glycoprotein of Japanese encephalitis, West Nile and Dengue viruses. Mol Immunol 1991;28: 149-154.
50. Leitmeyer KC, Vaughn DW, Watts DM, et al.: Dengue virus structural differences that correlate with pathogenesis. J Virol 1999;73:4738-4747.
51. Littaua R, Kurane I, and Ennis FA: Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 1990;144:3183-3186.
52. Lobigs M, Arthur CE, Mullbacher A, and Blanden RV: The Flavivirus non-structural protein NS3 is a dominant source of cytotoxic T cell peptide determinants. Virology 1994;202: 195-201.
53. Loke H, Bethell DB, Phuong CX, et al.: Strong HLA class I-restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis 2001;184:1369-1373.
54. Liu Y, Blanden RV, and Mullbacher A: Identification of cytolytic lymphocytes in West Nile virus-infected murine central nervous system. J Gen Virol 1989;70:565-573.
55. Mathews JH, Allan JE, Roehrig JT, Brubaker JR, and Hunt AR: T-helper cell and associated antibody response to synthetic peptides of the E glycoprotein of Murray Valley encephalitis virus. J Virol 1991;65:5141-5148.
56. Mathew A, and Rothman AL: Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev 2008;225:300-313.
57. Mathew A, Kurane I, Rothman AL, Zeng LL, Brinton MA, and Ennis FA: Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest 1996;98:1684-1691.
58. Mathur A, Kulshreshtha R, Rawat S, and Chaturvedi UC: Memory suppressor T cells in latent Japanese encephalitis virus infection. Immunology 1987;60:71-74.
59. Matveeva VA, Popova RV, Kvetkova EA, Chernicina LO, Zlobin VI, Puchovskaya NM, and Morozova OV: Antibodies against tick-borne encephalitis virus (TBEV) nonstructural and structural proteins in human sera and spinal fluid. Immunol Lett 1995;46:1-4.
60. Miller JD, van der Most RG, Akondy RS, et al.: Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008;28:710-722.
61. Monath TP. Yellow fever. In: The Arboviruses: Epidemiology and Ecology, Vol.5. (Monath TP, ed.). CRC Press, Boca Raton, FL, 1989. pp. 139-1123
62. Monath TP, Arroyo J, Levenbook I, Zhang Z-X, Catalan J, Draper K, and Guirakhoo F: Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol 2002;76:1932-1943.
63. Monath TP, and Heinz FX: Flaviviruses, Chapter 31. In: Fields Virology. (Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, and Roizmann B, eds.). Lippincott-Raven, Philadelphia, 1996, pp. 961-1034.
64. Monath TP: Yellow fever vaccine. Expert Rev Vaccines 2005;4:553-574.
65. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, et al.: T cell responses in dengue hemorrhagic fever: are crossreactive T cells suboptimal? J Immunol 2006;176:3821-3829.
66. Mongkolsapaya J, Dejnirattisai W, Xu XN, et al.: Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003;9:921-927.
67. Morens DM, and Halstead SB: Measurement of antibodydependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol 1990;71:2909-2914.
68. Murali-Krishna K, Ravi V, and Manjunath R: Cytotoxic T lymphocytes raised against Japanese encephalitis virus: effector cell phenotype, target specificity and in vitro virus clearance. J Gen Virol 1994;75(Pt 4):799-807.
69. Murphy FA, Fauquet CM, Bishop DHL, et al. (eds.): Virus Taxonomy: Classification and Nomenclature of Virus. Springer- Verlag, New York, 1995, pp. 415-421.
70. Murray K, Baraniuk S, Resnick M, et al.: Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect 2006;134:1325-1332.
71. Oliphant T, Engle M, Nybakken GE, et al.: Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005;11:522-530.
72. Phillpotts RJ, Stephenson JR, and Porterfield JS: Antibodydependent enhancement of tick-borne encephalitis virus infectivity. J Gen Virol 1985;66(Pt 8):1831-1837.
73. Pierson TC, and Diamond MS: Molecular mechanisms of antibody-mediated neutralization of Flavivirus infection. Expert Rev Mol Med 2008;10:e12.
74. Pierson TC, Fremont DH, Kuhn RJ, and Diamond MS: Structural insights into the mechanisms of antibodymediated neutralization of Flavivirus infection: implications for vaccine development. Cell Host Microbe 2008;4: 229-238.
75. Poland JD, Calisher CH, Monath TP, Downs WG, and Murphy K: Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981;59:895-900.
76. Pruitt AA: Central nervous system infections in cancer patients. Semin Neurol 2004;24:435-452.
77. Pugachev KV, Ocran SW, Guirakhoo F, Furby D, and Monath TP: Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine 2002;20:996-999.
78. Putnak JR, and Schlesinger JJ: Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J Gen Virol 1990;71:1697-1702.
79. Querec T, Bennouna S, Alkan S, et al.: Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006;203:413-424.
80. Reinhardt B, Jaspert R, Niedrig M, Kostner C, and L'age- Stelvr J: Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998;56:159-167.
81. Rico-Hesse R: Dengue virus evolution and virulence models. Clin Infect Dis 2007;44:1462-1466.
82. Robertson SE, Hull BP, Tomori O, Bele O, LeDuc JW, and Esteves K: Yellow fever: A decade of reemergence. JAMA 1996;276:1157-1162.
83. Roehrig JT, Bolin RA, and Kelly RG: Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998;246:317-328.
84. Roehrig JT, Hunt AR, Johnson AJ, and Hawkes RA: Synthetic peptides derived from the deduced amino acid sequence of the E-glycoprotein of Murray Valley encephalitis virus elicit antiviral antibody. Virology 1989;171:49-60.
85. Rothman AL: Immunology and immunopathogenesis of dengue disease. Adv Virus Res 2003;60:397-419.
86. Rothman AL: Dengue: defining protective versus pathologic immunity. J Clin Invest 2004;113:946-951.
87. Rothman AL, Kurane I, and Ennis FA: Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus. J Virol 1996;70:6540-6546.
88. Sabin AB, and Schlesinger RW: Production of immunity to dengue with virus modified by propagation in mice. Science 1945;101:640-642.
89. Schlesinger JJ, Brandriss MW, and Walsh EE: Protection against 17D yellow fever encephalitis in mice by passive transfer monoclonal antibodies to the non-structural glycoprotein gp48 and by active immunization with gp48. J Immunol 1985;135:2805-2809.
90. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, and Harris E: Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 2004;78:2701-2710.
91. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, and Harris E: Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 2006;80:10208-10217.
92. Simmons CP, Dong T, Chau NV, et al.: Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol 2005;79:5665-5675.
93. Sitati EM, and Diamond MS: CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol 2006;80:12060-12069.
94. Stiasny KS, Kiermayr S, Holzmann H, and Heinz FX: Cryptic properties of a cluster of dominant Flavivirus crossreactive antigenic sites. J Virol 2006;80:9557-9568.
95. Tesh RB, Guzman H, da Rosa AP, et al.: Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 2001;183:1431-1436.
96. Timofeev AV, Ozherelkov SV, Pronin AV, Deeva AV, Karaganova GG, Elbert LB, and Stephenson JR: Immunological basis for protection in a murine model of tickborne encephalitis by a recombinant adenovirus carrying the gene encoding the NS1 non-structural protein. J Gen Virol 1998;79:689-695.
97. Timofeev AV, Butenko VM, and Stephenson JR: Genetic vaccination of mice with plasmids encoding the NS1 nonstructural protein from tick-borne encephalitis virus and dengue 2 virus. Virus Genes 2004;28:85-97.
98. Valdes K, Alvarez M, Pupo M, Vazquez S, Rodriguez R, and Guzman MG: Human dengue antibodies against structural and nonstructural proteins. Clin Diagn Lab Immunol 2000;7:856-857.
99. van den Hurk AF, Ritchie SA, and Mackenzie JS: Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 2009;54:17-35.
100. van der Most RG, Harrington LE, Giuggio V, Mahar PL, and Ahmed R: Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 2002;296:117-124.
101. Vaughan K, Blythe M, Greenbaum J, Zhang Q, Peters B, Doolan D, and Sette A: Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues. Parasite Immunol 2009;32:78-97.
102. Vazquez S, Guzman M, Guillen G, et al.: Immune response to synthetic peptides of dengue prM protein. Vaccine 2002;20:1823-1830.
103. Wallace MJ, Smith DW, Broom AK, Mackenzie JS, Hall RA, Shellam GR, and McMinn PC: Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol 2003;84:1723-1728.
104. Wang E, Ni H, Xu R, Barrett AD, Watowich SJ, Gubler DJ, and Weaver SC: Evolutionary relationships of endemic/ epidemic and sylvatic dengue viruses. J Virol 2000;74:3227-3234.
105. Wang T, Scully E, Yin Z, et al.: IFNg-producing gd-T cells help control murine West Nile virus infection. J Immunol 2003;171:2524-2531.
106. Watts DM, Porter KR, Putvatana P, Vasquez B, Calampa C, Hayes CG, and Halstead SB: Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet 1999;354:1431-1434.
107. World Health Organization. Dengue fact sheet. www .who.int/topics/dengue/ en/
108. World Health Organization 2. Yellow fever fact sheet. www.who.int/topics/yellow-fever/en/
109. Wong SJ, Boyle RH, Demarest VL, et al.: Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. J Clin Microbiol 2003;41:4217-4223.
110. Xiao SY, Zhang H, Guzman H, and Tesh RB: Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis 2001;183:1437-1444.
111. Yauch LE, and Shresta S: Mouse models of dengue virus infection and disease. Antiviral Res 2008;80:87-93.
112. Zarebski L, Vaughan K, Sidney J, et al.: Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines 2008;7:55-74.
113. Zivna I, Green S, Vaughn DW, et al.: T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol 2002;168:5959-5965.